Oncimmune Holdings PLC services

EarlyCDT is a simple blood test that detects the elevated presence of autoantibodies generated by the body`s immune system as a natural defence against cancer cells. EarlyCDT Lung is the world’s most thoroughly validated blood test for the detection of lung cancer and requires only a small volume of blood which can be taken in the community setting as well as a doctor’s surgery. Shown to detect lung cancer on average four years earlier compared to current standard clinical diagnosis, EarlyCDT Lung can also provide an effective assessment of cancer risk in indeterminate pulmonary nodules (IPNs).

Viewing cancer through the immune lens (immuno-oncology) has led to the most promising advancements in cancer treatment in recent history, nonetheless the full potential of the approach is as yet unrealised.

There has been an unprecedented response to the COVID-19 pandemic from the life sciences industry and research institutions to understand and respond to the effects of COVID-19, but despite first generation vaccines now being deployed to fight the disease, the need to expand our understanding of the immune response to SARS-CoV-2 still exists. Autoimmune reactions to the virus have been shown to be a key factor in understanding long COVID.

Autoimmune disease is caused by the breaking of self-tolerance. Oncimmune’s understanding of the immune system as a mediator of disease powers the ImmunoINSIGHTS service for autoimmune disease.